Diaceutics Secures £11.5M Contract with Partner Therapeutics to Commercialize Oncology Precision Medicine BIZENGRI
核心洞察
Belfast-based Diaceutics (搜索) has signed a multi-year contract worth up to £11.5 million with Partner Therapeutics to commercialize the oncology (搜索) precision medicine BIZENGRI (zenocutuzumab).
The agreement leverages Diaceutics (搜索)' DXRX platform and PMx commercialization solutions to identify patients based on genomic profiles and accelerate optimal treatment delivery.
The contract includes £4.5 million in recurring service revenues through September 2026, with potential extension to 2028 that would add another £7 million in revenue.
Belfast-based pharmaceutical technology provider Diaceutics (搜索) PLC has secured a multi-million pound contract with US firm Partner Therapeutics to commercialize the oncology (搜索) precision medicine BIZENGRI (zenocutuzumab - zbco (搜索)). The extended multi-year partnership is valued at up to £11.5 million and represents a significant advancement in precision medicine commercialization.
The agreement, announced on March 26, 2025, will see Diaceutics (搜索) deploy its PMx commercialization solutions to support Partner Therapeutics, the new US license holder for BIZENGRI. This contract supersedes a previous arrangement announced in August 2024 with the former license holder.
Contract Details and Financial Impact
Under the terms of the agreement, Diaceutics (搜索) will initially provide its commercialization solutions through September 2026, generating up to £4.5 million in recurring service revenues. The contract includes annual autorenewal provisions that could extend the partnership through September 2028, potentially adding another £7 million in recurring service revenue.
Ryan Keeling, Diaceutics (搜索)' Chief Executive Officer, expressed enthusiasm about the collaboration: "We're excited to be working with Partner Therapeutics as they commercialize this novel and important therapy for patients with unmet needs. Our platform will enable Partner Therapeutics to identify and ensure patients get the opportunity to be treated with the optimal oncology (搜索) therapy as fast as possible."
The new contract structure represents an evolution from the previous arrangement, replacing contingent milestone fees with guaranteed recurring service fees. Diaceutics (搜索) has already recognized £1.5 million in service fee revenue from the original PMx contract during its first 10 months through April 1, 2025.
PMx: A Revolutionary Commercialization Approach
At the core of this partnership is Diaceutics (搜索)' PMx commercialization service, designed to combine all of the company's unique solutions to ensure patients are identified based on their genomic profiles and offered optimal treatment as quickly as possible.
The PMx service integrates Diaceutics (搜索)' daily Signal product with the comprehensive DXRX platform services, including:
- Patient identification
- Patient recruitment
- Diagnostic test adoption and optimization
- Physician engagement and education
This approach represents a novel commercialization solution that allows pharmaceutical and biotech companies to launch precision medicines in a more agile way while accelerating adoption and maximizing patient therapy access—a methodology Diaceutics (搜索) describes as "revolutionary for the precision medicine market."
Technology-Driven Precision Medicine Delivery
Under the agreement, Diaceutics (搜索) will leverage its DXRX platform's capabilities, specifically its genomic lab data, lab network, omni-channel marketing, and digital and peer-to-peer physician education resources to enable the commercialization of BIZENGRI.
The platform's technology-driven approach aims to address a critical challenge in precision medicine: ensuring that patients with specific genomic profiles receive the appropriate targeted therapies promptly. This is particularly important for oncology (搜索) treatments like BIZENGRI, where timely intervention can significantly impact patient outcomes.
Market Significance and Industry Impact
This partnership highlights the growing importance of specialized commercialization strategies for precision medicines. Traditional pharmaceutical marketing approaches often fall short for targeted therapies that require specific diagnostic testing to identify eligible patients.
The Diaceutics (搜索)-Partner Therapeutics collaboration demonstrates how technology platforms can bridge the gap between diagnostic testing and treatment delivery, potentially establishing a new standard for precision medicine commercialization.
For Diaceutics (搜索), this contract reinforces its position as a leading technology and services provider to the pharmaceutical and biotech industry. The company's DXRX platform continues to gain traction as a valuable tool for precision medicine commercialization, offering a comprehensive solution that addresses the unique challenges of bringing targeted therapies to market.
About the Companies
Diaceutics (搜索) PLC, listed on AIM (DXRX), is a technology and services provider to the pharmaceutical and biotech industry. The company's mission centers on ensuring every patient receives the right test and therapy to positively impact their disease outcome.
Partner Therapeutics is an integrated biotechnology company focused on developing and commercializing therapeutics to improve health outcomes in cancer (搜索) and other serious diseases. The company emphasizes delivering products and supporting medical teams to achieve superior outcomes for patients and their families.
BIZENGRI (zenocutuzumab) is an oncology (搜索) precision medicine now licensed to Partner Therapeutics for the US market. Complete prescribing information, including boxed warnings, is available at www.bizengri.com.